These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity. Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368 [TBL] [Abstract][Full Text] [Related]
23. RECQL5: Another DNA helicase potentially involved in hereditary breast cancer susceptibility. Tavera-Tapia A; de la Hoya M; Calvete O; Martin-Gimeno P; Fernández V; Macías JA; Alonso B; Pombo L; de Diego C; Alonso R; Pita G; Barroso A; Urioste M; Caldés T; Newman JA; Benítez J; Osorio A Hum Mutat; 2019 May; 40(5):566-577. PubMed ID: 30817846 [TBL] [Abstract][Full Text] [Related]
24. Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report. Andrés R; Menao S; Arruebo M; Quílez E; Cardiel MJ Breast Cancer Res Treat; 2019 Oct; 177(3):767-770. PubMed ID: 31292799 [TBL] [Abstract][Full Text] [Related]
25. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer. Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444 [TBL] [Abstract][Full Text] [Related]
26. Contributions of ATM mutations to familial breast and ovarian cancer. Thorstenson YR; Roxas A; Kroiss R; Jenkins MA; Yu KM; Bachrich T; Muhr D; Wayne TL; Chu G; Davis RW; Wagner TM; Oefner PJ Cancer Res; 2003 Jun; 63(12):3325-33. PubMed ID: 12810666 [TBL] [Abstract][Full Text] [Related]
27. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry. Graña B; Fachal L; Darder E; Balmaña J; Ramón Y Cajal T; Blanco I; Torres A; Lázaro C; Diez O; Alonso C; Santamariña M; Velasco A; Teulé A; Lasa A; Blanco A; Izquierdo A; Borràs J; Gutiérrez-Enríquez S; Vega A; Brunet J Breast Cancer Res Treat; 2011 Jul; 128(2):573-9. PubMed ID: 21445571 [TBL] [Abstract][Full Text] [Related]
28. Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample. Yoshida R; Hagio T; Kaneyasu T; Gotoh O; Osako T; Tanaka N; Amino S; Yaguchi N; Nakashima E; Kitagawa D; Ueno T; Ohno S; Nakajima T; Nakamura S; Miki Y; Hirota T; Takahashi S; Matsuura M; Noda T; Mori S Cancer Sci; 2021 Mar; 112(3):1310-1319. PubMed ID: 33421217 [TBL] [Abstract][Full Text] [Related]
29. Challenges in Interpreting Germline Mutations in BARD1 and ATM in Breast and Ovarian Cancer Patients. DeLeonardis K; Sedgwick K; Voznesensky O; Matloff E; Hofstatter E; Balk S; Tung N Breast J; 2017 Jul; 23(4):461-464. PubMed ID: 28139868 [TBL] [Abstract][Full Text] [Related]
30. Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families. Lindeman GJ; Hiew M; Visvader JE; Leary J; Field M; Gaff CL; Gardner RJ; Trainor K; Cheetham G; Suthers G; Kirk J Breast Cancer Res; 2004; 6(4):R401-7. PubMed ID: 15217508 [TBL] [Abstract][Full Text] [Related]
31. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families. Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550 [TBL] [Abstract][Full Text] [Related]
32. Identification of hereditary breast and ovarian cancer germline variants in Granada (Spain): NGS perspective. Molina-Zayas M; Garrido-Navas C; García-Puche JL; Barwell J; Pedrinaci S; Atienza MM; García-Linares S; de Haro-Muñoz T; Lorente JA; Serrano MJ; Poyatos-Andújar A Mol Genet Genomics; 2022 May; 297(3):859-871. PubMed ID: 35451682 [TBL] [Abstract][Full Text] [Related]
33. Apparent regional differences in the spectrum of BARD1 pathogenic variants in Spanish population and importance of copy number variants. Benito-Sánchez B; Barroso A; Fernández V; Mercadillo F; Núñez-Torres R; Pita G; Pombo L; Morales-Chamorro R; Cano-Cano JM; Urioste M; González-Neira A; Osorio A Sci Rep; 2022 May; 12(1):8547. PubMed ID: 35595798 [TBL] [Abstract][Full Text] [Related]
35. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Díez O; Osorio A; Durán M; Martinez-Ferrandis JI; de la Hoya M; Salazar R; Vega A; Campos B; Rodríguez-López R; Velasco E; Chaves J; Díaz-Rubio E; Jesús Cruz J; Torres M; Esteban E; Cervantes A; Alonso C; San Román JM; González-Sarmiento R; Miner C; Carracedo A; Eugenia Armengod M; Caldés T; Benítez J; Baiget M Hum Mutat; 2003 Oct; 22(4):301-12. PubMed ID: 12955716 [TBL] [Abstract][Full Text] [Related]
36. Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). Blay P; Santamaría I; Pitiot AS; Luque M; Alvarado MG; Lastra A; Fernández Y; Paredes A; Freije JM; Balbín M BMC Cancer; 2013 May; 13():243. PubMed ID: 23683081 [TBL] [Abstract][Full Text] [Related]
37. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants. Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102 [TBL] [Abstract][Full Text] [Related]
38. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families. Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464 [TBL] [Abstract][Full Text] [Related]
39. Germline likely pathogenic variants in ataxia-telangiectasia-mutated gene in an Iranian family with hereditary diffuse gastric cancer without Kheirollahi M; Saneipour M; Moridnia A J Cancer Res Ther; 2021; 17(6):1434-1437. PubMed ID: 34916374 [TBL] [Abstract][Full Text] [Related]
40. The Identification by Exome Sequencing of Candidate Genes in BenAyed-Guerfali D; Kifagi C; BenKridis-Rejeb W; Ammous-Boukhris N; Ayedi W; Khanfir A; Daoud J; Mokdad-Gargouri R Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 35893033 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]